Related Experiment Video

Updated: Mar 7, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma

Nizar M Tannir1, Gisela Schwab2, Viktor Grünwald3

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler St., Unit 1374, Houston, TX, 77030, USA.

Current Oncology Reports
|March 2, 2017
PubMed

Insights

Cabozantinib is an effective second-line treatment for advanced clear cell renal cell carcinoma (RCC) after anti-angiogenic therapy. It significantly improves survival and response rates compared to everolimus in patients with RCC.

Area of Science:

  • Oncology
  • Translational Research
  • Pharmacology

Background:

  • Clear cell renal cell carcinoma (RCC) is linked to von Hippel-Lindau (VHL) gene inactivation.
  • VHL loss promotes tumor angiogenesis, making VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) a standard first-line treatment for advanced RCC.
  • Recent FDA approvals include nivolumab, cabozantinib, and lenvatinib/everolimus as second-line therapies post-anti-angiogenic treatment.

Purpose of the Study:

  • To summarize the translational research and clinical development of cabozantinib.
  • To highlight cabozantinib's approval as a second-line therapy for advanced RCC.

Main Methods:

  • Review of translational research and clinical trial data for cabozantinib in RCC.
  • Comparative analysis of cabozantinib versus everolimus in previously treated RCC patients.

Main Results:

  • Cabozantinib targets VEGFRs, MET, and AXL, kinases involved in RCC progression and resistance.
  • Cabozantinib demonstrated statistically significant improvements in overall survival, progression-free survival, and objective response rate compared to everolimus.
  • These findings support cabozantinib's efficacy in the second-line setting for advanced RCC.

Conclusions:

  • Cabozantinib represents a significant advancement in second-line treatment for advanced RCC.
  • The drug's multi-kinase inhibition profile contributes to its efficacy in patients previously treated with VEGFR TKIs.
Keywords:
AXLAngiogenesisCabozantinibMETRCCRenal cell carcinomaVEGF receptor

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
698
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
993